Security key
17331Y109
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 403,072
- Total 13F value
- $405,582
- Share change
- +50,241
- SEC-reported price per share
- $1.01
- Number of holders
- 3
- Value change
- +$49,224
- Number of buys
- 2
- Shares outstanding
- 93,629,159
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
3
Top holders
3
CTOR full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
CITIUS ONCOLOGY, INC. SEC filings
CITIUS ONCOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 17331Y109
Recent filing periods:
Ownership snapshot
Top reported holders of CTOR - CITIUS ONCOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Citius Pharmaceuticals, Inc.
Disclosed value leader
Citius Pharmaceuticals, Inc.
Comparable rows
2/15
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 71%
13 rows are not safely comparable across share classes.
13D/G row: Citius Pharmaceuticals, Inc.
Showing 1-6 of 15 holder rows.
Quick read
Citius Pharmaceuticals, Inc. leads the comparable SEC ownership view at 71%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Citius Pharmaceuticals, Inc.'s linked filing trail.
Comparable ownership
Top 2
Citius Pharmaceuticals, Inc.
71%
ARMISTICE CAPITAL, LLC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. |
13D/G
3/4/5
10%+ Owner
|
71%
Reported 13D/G
· 15 May 2026
|
$59,444,654
66,049,615 shares
|
$0 | 15 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
Reported 13D/G
· 30 Jun 2026
|
$6,547,487
9,353,553 shares
|
+$37,545 | 30 Jun 2026 |
| Dahe Zhang |
3/4/5
Chief Financial Officer, Director, 10%+ Owner
|
—
denominator unverified
|
—
1,725,000 shares
|
— | 13 Oct 2022 |
| Xiaofeng Yuan |
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
—
denominator unverified
|
—
1,725,000 shares
|
— | 13 Oct 2022 |
| Leonard L. Mazur |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$9,790,000
5,400,000 shares
mixed-class rows
|
— | 19 Sep 2025 |
| Myron Z. Holubiak |
3/4/5
Secretary, Director
|
—
mixed-class rows
|
$4,268,000
2,400,000 shares
mixed-class rows
|
— | 19 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
403,072
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
19
Q3 2026 holders
3
Holder diff
-16
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend